Moreover, selpercatinib was demonstrated to be effective towards a female patient with EMLA4-RET + NSCLC who progressed to agerafenib (an RAF inhibitor) developing leptomeningeal carcinomatosis attaining a PR with selpercatinib with a duration of response not estimable after a follow-up of 10.8 months [77]. This evidence concerns the gene RET and non-small cell lung carcinoma.